Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2018-02-22T00:56:07Z | - |
dc.date.available | 2018-02-22T00:56:07Z | - |
dc.date.issued | 2015-10 | - |
dc.identifier.citation | INTERNATIONAL JOURNAL OF PHARMACEUTICS, v. 494, No. 1, Page. 506-515 | en_US |
dc.identifier.issn | 0378-5173 | - |
dc.identifier.issn | 1873-3476 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0378517315301538 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/39299 | - |
dc.description.abstract | Nanoparticle albumin-bound (nab (TM)) technology is an effective way of delivering hydrophobic chemotherapeutics. We developed a one-pot/one-step formulation of paclitaxel (PTX)-bound albumin nanoparticles with embedded tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/PTX HSA-NP) for the treatment of pancreatic cancer. TRAIL/PTX HSA-NPs were fabricated using a high-pressure homogenizer at a TRAIL feeding ratio of 0.2%, 1.0%, and 2.0%. TRAIL/PTX HSA-NPs were spherical and became larger in size (170-230 nm) with increasing TRAIL amount (0.2-2.0%). The loading efficiencies of PTX were in the range of similar to 86.4% and significantly low at 2.0% TRAIL (60.4%). Specifically, the inhibitory concentrations (IC50) of TRAIL (1.0 or 2.0%)/PTX HSA-NPs were ˃20-fold lower than that of plain PTX-HSA NP (0.032 +/- 0.06, 0.022 +/- 0.005, and 0.96 +/- 0.15 ng/ml, respectively) in pancreatic Mia Paca-2 cells. Considering TRAIL loading, bioactivity, and particle size, TRAIL(1.0%)/PTX HSA-NPs were determined as the optimal candidate for further studies. TRAIL(1.0%)/PTX HSA-NPs displayed substantially greater apoptotic activity than plain PTX HSA-NP in both FACS and TUNEL analysis. The loaded PTX and TRAIL were gradually released from the TRAIL(1.0%)/PTX HSA-NPs until similar to 24 h, which is considered to be a sufficient time for delivery to the tumor tissue. TRAIL(1.0%)/PTX HSA-NP displayed markedly more antitumor efficacy than plain PTX HSA-NP in Mia Paca-2 cell-xenografted mice in terms of tumor volume (size) and weight (213.9 mm(3) and 0.18 g vs. 1126.8 mm(3) and 0.80 g, respectively). These improved in vitro and in vivo performances were due to the combined synergistic effects of PTX and TRAIL. We believe that this TRAIL/PTX HSA-NP would have potential as a novel apoptosis-based anticancer agent. (C) 2015 Elsevier B.V. All rights reserved. | en_US |
dc.description.sponsorship | This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and future Planning (#2014002133). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ELSEVIER SCIENCE BV | en_US |
dc.subject | Albumin | en_US |
dc.subject | Nanoparticles | en_US |
dc.subject | TRAIL | en_US |
dc.subject | Paclitaxel | en_US |
dc.subject | Pancreatic cancer | en_US |
dc.subject | Anti-cancer agent | en_US |
dc.subject | APOPTOSIS-INDUCING LIGAND | en_US |
dc.subject | IMPROVED ANTITUMOR-ACTIVITY | en_US |
dc.subject | DRUG-DELIVERY SYSTEMS | en_US |
dc.subject | LUNG-CANCER | en_US |
dc.subject | IN-VIVO | en_US |
dc.subject | TUMOR | en_US |
dc.subject | PROTEIN | en_US |
dc.subject | CELLS | en_US |
dc.subject | APO2L/TRAIL | en_US |
dc.subject | CHALLENGES | en_US |
dc.title | Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer | en_US |
dc.type | Article | en_US |
dc.relation.no | 1 | - |
dc.relation.volume | 494 | - |
dc.identifier.doi | 10.1016/j.ijpharm.2015.08.055 | - |
dc.relation.page | 506-515 | - |
dc.relation.journal | INTERNATIONAL JOURNAL OF PHARMACEUTICS | - |
dc.contributor.googleauthor | Min, SY | - |
dc.contributor.googleauthor | Byeon, HJ | - |
dc.contributor.googleauthor | Lee, CK | - |
dc.contributor.googleauthor | Seo, JS | - |
dc.contributor.googleauthor | Lee, ES | - |
dc.contributor.googleauthor | Shin, BS | - |
dc.contributor.googleauthor | Choi, HG | - |
dc.contributor.googleauthor | Lee, KC | - |
dc.contributor.googleauthor | Youn, YS | - |
dc.relation.code | 2015002419 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.